HCV NUCLEIC ACID VACCINE STUDIES IN CHIMPANZEES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 资金来源：NIDDK合同269-MK-609143 丙型肝炎病毒是慢性肝病的主要病因，据估计，全世界有超过2亿人受到感染。约70%的接触丙型肝炎的人发展为持续性感染和慢性肝炎，约20%的慢性感染者发展为肝硬变，约5%的肝硬化者发展为终末期肝癌。目前还没有有效的疫苗来预防感染或 免疫治疗与抗病毒治疗相结合。因此，研究疫苗策略对丙型肝炎病毒感染的预防和免疫治疗具有重要意义。在这个项目中，我们正在黑猩猩模型中研究一种新的疫苗策略，以确定其预防感染的有效性。这项研究的结果有望为开发安全有效的疫苗提供关键信息。 人类。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Funding source: NIDDK contract 269-MK-609143 Hepatitis C Virus (HCV) is the major cause of chronic liver disease and its estimated that more than 200 million people are infected world wide. Approximately 70 % of the persons exposed to HCV develop persistent infection and chronic hepatitis and approximately 20% of the chronically mfected persons develop cirrhosis and about 5% with cirrhosis develop end stage liver cancer. There is no effective vaccine for the prevention of infection or for immunotherapy in conjunction with antiviral therapy. Therefore, it is important to investigate vaccine strategies for prevention and immunotherapy of HCV infection. In this project, we are investigating a novel vaccine strategy in the chimpanzee model to determine its efficacy in preventing infection. Outcome from this study is expected to provide critical information for the development of a safe and effective vaccine for humans.